ERBB2 and breast carcinoma: Indeed, genomic mutations are not always associated with activated signalling pathways and, conversely, pathway activation can occur in the absence of mutations, as exemplified by PIK3CA3 and human epidermal growth factor receptor 2 (Her2, also known as ErbB2) signalling4 in breast cancer.